ClinicalTrials.gg
CompletedNCT02581891ARIESUpdated Nov 8, 2023Results posted

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

A Phase 4 interventional study of Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) and Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Bayer. Completed at 39 sites in 8 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
17th of 66
287 · median 55
Started
2015
with 5 others
Phase 4
27 of 66
none open now
Registered
38th of 66
by date
Lead sponsor
8 of 66
Bayer

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 17th largest by enrollment, is one of 6 that started in 2015, is one of 27 in phase 4, and was the 38th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.

Read the detailed description

The T\&E dosing regimen for nAMD has emerged as a preferred regimen for many treating physicians aiming at maximizing outcomes by proactively treating the subject at each visit and by extending the treatment interval (if extension criteria are met), thus limiting visits, monitoring, and injections.

To this day, there is limited evidence available addressing the question of what are useful intervals for treating and monitoring, how do they differ among subjects, and how are retreatment criteria applied to achieve long-term desirable outcomes in real-life practice. This study is designed to evaluate the optimal use, efficacy, and safety of the T\&E regimen with intravitreal aflibercept in subjects with nAMD.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Neovascular age-related macular degeneration
  • nAMD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 50 years of age.
  • Active primary subfoveal CNV lesions secondary to nAMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye. Patients with polypoidal choroidal vasculopathy or retinal angiomatous proliferation are eligible to participate in the study, and their condition should be captured in the eCRF.
  • ETDRS BCVA of 73 to 25 letters (20/40 to 20/320 Snellen equivalent) in the study eye.
  • The area of CNV must occupy at least 50% of the total lesion.

Exclusion criteria

Exclusion Criteria:

  • Any prior ocular (in the study eye) or systemic treatment or surgery for nAMD, except dietary supplements or vitamins.
  • Any prior or concomitant therapy with another agent to treat nAMD in the study eye.
  • Prior treatment with anti-VEGF agents as follows:
  • Prior treatment with anti-VEGF therapy in the study eye is not allowed
  • Prior treatment with anti-VEGF therapy in the fellow eye with an investigational agent (not approved, e.g. bevacizumab) within the last 3 months before the first dose in the study. Such treatment will also not be allowed during the study. Prior treatment with an approved anti-VEGF therapy in the fellow eye is allowed.
  • Prior systemic anti-VEGF therapy, investigational or approved, within the last 3 months before the first dose in the study, and such treatment will not be allowed during the study.
  • Total lesion size >12 disc areas (30.5 mm2, including blood, scars and neovascularization) as assessed by FA in the study eye.
  • Subretinal hemorrhages that are either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).
  • Scar or fibrosis making up >50% of the total lesion in the study eye.
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    Early-start T&E / Arm 1

    Early-start T\&E arm: test group, early treatment individualization

    Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

  • Active comparator
    Late-start T&E / Arm 2

    Late-start T\&E arm; per label, control group, treatment individualization after Year 1

    Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in BCVA as Measured by the ETDRS Letter Score

    BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.

    Time frame: From Week 16 to Week 104

Secondary outcomes

  1. Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline

    Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.

    Time frame: at Week 104

  2. Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52

    BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.

    Time frame: from baseline to Week 52, baseline to Week 104, and Week 16 to Week 52

  3. Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline

    Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.

    Time frame: At week 52

  4. Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline

    Participants gained 3 lines (15 letters) in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.

    Time frame: At Week 52 and Week 104

  5. Change in Central Retinal Thickness (CRT)

    CRT were evaluated using spectral domain Optical coherence tomograph (OCT).

    Time frame: From baseline to Week 52, baseline to Week 104, Week 16 to Week 52, and Week 16 to Week 104

  6. Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104

    Time frame: At Week 52 and Week 104

  7. Duration of Last Treatment Interval

    Time frame: Early-Start T&E: from week 16 up to Week 104 or early termination; Late-Start T&E: From end of Year 1 up to Week 104 or early termination

  8. Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Treatment Interval

    Time frame: at 8 weeks, 10 weeks, 12 weeks, 14 weeks, and 16 weeks

07

Results

Posted May 21, 2020

Participant flow

This study was conducted from 19-Nov-2015 (First Patient First Visit) to 26-Apr-2019 (Last Patient Last Visit).

Participant flow — Overall Study
MilestoneEarly-start T&E ArmLate-start T&E Arm
Started135136
Completed treatment120117
Completed119117
Not completed1619
Withdrew: Adverse event46
Withdrew: Death34
Withdrew: Lost to follow-up12
Withdrew: Physician decision01
Withdrew: Withdrawal by subject45
Withdrew: Other reasons31
Withdrew: Discontinued during followup10

Outcome measures

PrimaryChange in BCVA as Measured by the ETDRS Letter Score

BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.

Time frame:
From Week 16 to Week 104
Reported as:
Mean · Letters correctly read
Change in BCVA as Measured by the ETDRS Letter Score
Letters correctly readEarly-start T&E ArmLate-start T&E Arm
Change in BCVA as Measured by the ETDRS Letter Score-2.1 ± 11.4-0.4 ± 8.4
Statistical analysis
  • Early-start T&E Arm vs Late-start T&E Arm · ANCOVA · p = 0.0162 · Ls mean difference: -2.0199 · 95% CI -4.7470 to 0.7073
SecondaryPercentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline

Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.

Time frame:
at Week 104
Reported as:
Number · Percentage
Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline
PercentageEarly-start T&E ArmLate-start T&E Arm
Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline93.496.2
SecondaryChange in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52

BCVA (best corrected visual acuity) was measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters; a higher score represents better functioning.

Time frame:
from baseline to Week 52, baseline to Week 104, and Week 16 to Week 52
Reported as:
Mean · Letters
Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52
LettersEarly-start T&E ArmLate-start T&E Arm
From baseline to Week 527.8 ± 9.410.2 ± 9.3
From baseline to Week 1044.3 ± 13.47.9 ± 11.9
Week 1666.7 ± 13.069.6 ± 11.6
From Week 16 to Week 521.3 ± 6.42.0 ± 5.3
SecondaryPercentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline

Participants maintained 3 lines (15 letters) vision loss in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.

Time frame:
At week 52
Reported as:
Number · Percentage
Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline
PercentageEarly-start T&E ArmLate-start T&E Arm
Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline100.0100.0
SecondaryPercentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline

Participants gained 3 lines (15 letters) in BCVA (Best-corrected visual acuity) as measured by the ETDRS (Early Treatment Diabetic Retinopathy Study) letter.

Time frame:
At Week 52 and Week 104
Reported as:
Number · Percentage
Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline
PercentageEarly-start T&E ArmLate-start T&E Arm
Week 5219.827.9
Week 10418.922.1
SecondaryChange in Central Retinal Thickness (CRT)

CRT were evaluated using spectral domain Optical coherence tomograph (OCT).

Time frame:
From baseline to Week 52, baseline to Week 104, Week 16 to Week 52, and Week 16 to Week 104
Reported as:
Mean · μm
Change in Central Retinal Thickness (CRT)
μmEarly-start T&E ArmLate-start T&E Arm
From baseline to Week 52-164.9 ± 117.3-167.1 ± 117.1
From baseline to Week 104-161.6 ± 135.6-158.6 ± 125.1
Week 16321.4 ± 93.4322.5 ± 104.0
From Week 16 to Week 52-28.5 ± 56.3-28.7 ± 54.0
From Week 16 to Week 104-25.1 ± 68.9-20.2 ± 70.0
SecondaryNumber of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104
Time frame:
At Week 52 and Week 104
Reported as:
Mean · injections
Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104
injectionsEarly-start T&E ArmLate-start T&E Arm
Week 527.1 ± 0.88.0 ± 0.2
Week 10412.0 ± 2.313.0 ± 1.8
SecondaryDuration of Last Treatment Interval
Time frame:
Early-Start T&E: from week 16 up to Week 104 or early termination; Late-Start T&E: From end of Year 1 up to Week 104 or early termination
Reported as:
Mean · Weeks
Duration of Last Treatment Interval
WeeksEarly-start T&E ArmLate-start T&E Arm
Duration of Last Treatment Interval11.5 ± 3.711.4 ± 3.7
SecondaryPercentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Treatment Interval
Time frame:
at 8 weeks, 10 weeks, 12 weeks, 14 weeks, and 16 weeks
Reported as:
Number · percentage
Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Treatment Interval
percentageEarly-start T&E ArmLate-start T&E Arm
<8 weeks5.77.7
8 weeks27.429.8
10 weeks19.810.6
12 weeks8.513.5
14 weeks8.511.5
16 weeks25.525.0
>16 weeks4.71.9

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were AEs that started after the first application of aflibercept up to 30 days after last study drug Injection in the study. TEAEs were collected from Week 0 till End of study/Week 104 or early termination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early-start T&E Arm3/135 (2.2%)29/135 (21.5%)93/135 (68.9%)
Late-start T&E Arm4/136 (2.9%)35/136 (25.7%)80/136 (58.8%)
Treated, But Not Randomized0/16 (0%)3/16 (18.8%)10/16 (62.5%)
Most frequent serious events
Showing 10 of 96
Most frequent serious events
EventEarly-start T&E ArmLate-start T&E ArmTreated, But Not Randomized
Cerebrovascular accidentNervous system disorders1/1350/1362/16
Acute myocardial infarctionCardiac disorders0/1351/1361/16
PneumoniaInfections and infestations3/1355/1360/16
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations3/1350/1360/16
Cardiac failure congestiveCardiac disorders2/1350/1360/16
Abdominal painGastrointestinal disorders2/1350/1360/16
Inguinal herniaGastrointestinal disorders2/1351/1360/16
Cholecystitis acuteHepatobiliary disorders2/1352/1360/16
InfluenzaInfections and infestations2/1350/1360/16
Visual acuity reducedEye disorders0/1352/1360/16
Most frequent other events
Showing 10 of 28
Most frequent other events
EventEarly-start T&E ArmLate-start T&E ArmTreated, But Not Randomized
Visual acuity reducedEye disorders21/13517/1361/16
Conjunctival haemorrhageEye disorders20/13518/1360/16
NasopharyngitisInfections and infestations18/13517/1360/16
Retinal haemorrhageEye disorders4/1356/1362/16
Neovascular age-related macular degenerationEye disorders15/13514/1361/16
HypertensionVascular disorders13/13511/1360/16
InfluenzaInfections and infestations11/13512/1360/16
BlepharitisEye disorders2/13511/1360/16
Dry eyeEye disorders6/13511/1360/16
Punctate keratitisEye disorders10/1355/1361/16

Baseline characteristics

All 271 participants were included in the SAF (287), who received any study drug in this study. 269 participants were included in the FAS, excluding 16 participants who were treated but not randomized and 1 participant in each treatment arm from SAF. Of the 269 participants in FAS, 59 participants in total were excluded from the PPS (210).

Age, Continuous
Age, Continuous(Years)Early-start T&E ArmLate-start T&E ArmTotal
Mean76 ± 8.876.9 ± 8.276.5 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Early-start T&E ArmLate-start T&E ArmTotal
Female8173154
Male5463117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Early-start T&E ArmLate-start T&E ArmTotal
Hispanic or Latino3710
Not Hispanic or Latino126122248
Unknown or Not Reported6713
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Early-start T&E ArmLate-start T&E ArmTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American101
White131127258
More than one race000
Unknown or Not Reported189
Baseline BCVA letters scores (study eye)
Baseline BCVA letters scores (study eye)(letters)Early-start T&E ArmLate-start T&E ArmTotal
Mean60.2 ± 12.161.3 ± 10.860.8 ± 11.4
Baseline CRT
Baseline CRT(μm)Early-start T&E ArmLate-start T&E ArmTotal
Mean443.7 ± 120.0448.3 ± 133.1446.0 ± 126.4
08

Study locations

39 sites
  • Strathfield, New South Wales 2135, Australia
  • Sydney, New South Wales 2000, Australia
  • Westmead, New South Wales 2145, Australia
  • East Melbourne, Victoria 3002, Australia
  • Launceston, 7249, Australia
  • Hamilton, Ontario L8G 5E4, Canada
  • Ottawa, Ontario K2B7E9, Canada
  • Boisbriand, Quebec J7H1S6, Canada
  • Creteil Cedex, 94010, France
  • Nice cedex 1, 06006, France
  • Freiburg, Baden-Württemberg 79106, Germany
  • Tübingen, Baden-Württemberg 72076, Germany
  • Hannover, Niedersachsen 30625, Germany
  • Bonn, Nordrhein-Westfalen 53105, Germany
  • Köln, Nordrhein-Westfalen 50924, Germany
  • Sulzbach, Saarland 66280, Germany
  • Chemnitz, Sachsen 09116, Germany
  • Berlin, 10713, Germany
  • Budapest, 1062, Hungary
  • Budapest, 1085, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1115, Hungary
  • Budapest, 1125, Hungary
  • Budapest, 1133, Hungary
  • Debrecen, 4032, Hungary
  • Pecs, 7621, Hungary
  • Szombathely, 9700, Hungary
  • Roma, Lazio 00198, Italy
  • Milano, Lombardia 20132, Italy
  • Milano, Lombardia 20157, Italy
  • Padova, Veneto 35128, Italy
  • Oviedo, Asturias 33012, Spain
  • Madrid, Spain
  • Zaragoza, 50009, Spain
  • Canterbury, Kent CT1 3NG, United Kingdom
  • Bristol, BS12LX, United Kingdom
  • Liverpool, L7 8XP, United Kingdom
  • London, EC1V2PD, United Kingdom
  • Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Wolf S, Holz FG, Midena E, Souied EH, Lambrou G, Machewitz T, Allmeier H, Mitchell P; ARIES Study Investigators. Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis. Ophthalmol Ther. 2022 Oct;11(5):1793-1803. doi: 10.1007/s40123-022-00541-8. Epub 2022 Jul 12. PubMed 35821380 ↗
  • Chaudhary V, Holz FG, Wolf S, Midena E, Souied EH, Allmeier H, Lambrou G, Machewitz T, Mitchell P; ARIES study investigators. Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis. Ophthalmol Ther. 2022 Jun;11(3):1119-1130. doi: 10.1007/s40123-022-00491-1. Epub 2022 Mar 18. PubMed 35303285 ↗
  • Tuerksever C, Somfai GM, Oesch S, Machewitz T, Hasler PW, Zweifel S. Hypothetical Switch of Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis. Ophthalmol Ther. 2022 Apr;11(2):613-627. doi: 10.1007/s40123-021-00448-w. Epub 2022 Jan 23. PubMed 35066801 ↗
  • Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S; ARIES study investigators. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. Retina. 2021 Sep 1;41(9):1911-1920. doi: 10.1097/IAE.0000000000003128. Erratum In: Retina. 2022 Sep 01;42(9):e43. doi: 10.1097/IAE.0000000000003560. PubMed 33782365 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Apr 2019, 41 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 41 months is above that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2015
First posted
Oct 21, 2015
StartActual
Nov 19, 2015
Primary completionActual
Apr 26, 2019
CompletionActual
Apr 26, 2019
Results first posted
May 21, 2020
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02581891
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Nov 19, 2015
Primary completion
Apr 26, 2019
Completion
Apr 26, 2019
Results posted
May 21, 2020
Last update
Nov 8, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion